First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors.
Martin WermkeTobias A W HolderriedJason John LukeVan K MorrisWinfried H AlsdorfKatrin WetzkoBorje S AnderssonIgnacio I WistubaEdwin R ParraMohammad B HossainSandra Grund-GröschkeKatrin AslanArun SatelliAnantha MarisettySwapna SatamMamta KalraJens HukelmannM Alper KursunelKarine PozoAndreas AcsLinus BackertMelissa BaumeisterSebastian BunkClaudia WagnerOliver SchoorAli S MohamedAndrea Mayer-MoklerNorbert HilfDelfi KrishnaSteffen WalterApostolia-Maria TsimberidouCedrik M BrittenPublished in: Journal for immunotherapy of cancer (2024)
NCT04639245, NCT05430555.
Keyphrases
- cell therapy
- stem cells
- endothelial cells
- mesenchymal stem cells
- acute lymphoblastic leukemia
- acute myeloid leukemia
- study protocol
- clinical trial
- phase iii
- open label
- regulatory t cells
- multiple myeloma
- diffuse large b cell lymphoma
- phase ii
- induced pluripotent stem cells
- hodgkin lymphoma
- pluripotent stem cells
- randomized controlled trial
- bone marrow
- immune response